These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 25995319)
41. Letter by Banker et al regarding article, "cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial". Banker J; Rosenheck S; Gotsman I Circulation; 2013 Oct; 128(14):e216. PubMed ID: 24081958 [No Abstract] [Full Text] [Related]
42. Letter by Dai et al regarding article, "cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial". Dai H; Guang X; Xiao Z Circulation; 2013 Oct; 128(14):e217. PubMed ID: 24081959 [No Abstract] [Full Text] [Related]
44. Interplay between right ventricular function and cardiac resynchronization therapy: an analysis of the CARE-HF trial (Cardiac Resynchronization-Heart Failure). Damy T; Ghio S; Rigby AS; Hittinger L; Jacobs S; Leyva F; Delgado JF; Daubert JC; Gras D; Tavazzi L; Cleland JG J Am Coll Cardiol; 2013 May; 61(21):2153-60. PubMed ID: 23541971 [TBL] [Abstract][Full Text] [Related]
45. Prevalence of potential cardiac resynchronization therapy candidates and actual use of cardiac resynchronization therapy in patients hospitalized for heart failure. De Sutter J; Weytjens C; Van de Veire N; Provenier F; Vande Kerckhove B; Willems AM; De Laet N; Van Camp G Eur J Heart Fail; 2011 Apr; 13(4):412-5. PubMed ID: 21138909 [No Abstract] [Full Text] [Related]
46. Troponin leak in heart failure: moving forward to arrest cardiomyocyte attrition and promote myocardial regeneration. Tan LB; Hothi SS; Tan DK Int J Cardiol; 2013 Jan; 162(3):137-9. PubMed ID: 22357426 [No Abstract] [Full Text] [Related]
47. Echocardiographic mapping of left ventricular resynchronization during cardiac resynchronization therapy procedures. Chan NY; Choy CC; Cheung KC; Lau CL; Lo YK; Chu PS; Yuen HC; Lau ST; Choi YC Chin Med J (Engl); 2010 Jul; 123(13):1645-51. PubMed ID: 20819622 [TBL] [Abstract][Full Text] [Related]
48. Acute effects of cardiac resynchronization therapy on arterial distensibility and serum norepinephrine levels in advanced heart failure. Yildiz M; Hasdemir H; Turkkan C; Astarcioglu MA; Alper AT; Sahin A; Ozkan M Cardiol J; 2013; 20(3):304-9. PubMed ID: 23788305 [TBL] [Abstract][Full Text] [Related]
49. Influence of diabetes on cardiac resynchronization therapy in heart failure patients: a meta-analysis. Sun H; Guan Y; Wang L; Zhao Y; Lv H; Bi X; Wang H; Zhang X; Liu L; Wei M; Song H; Su G BMC Cardiovasc Disord; 2015 Mar; 15():25. PubMed ID: 25880202 [TBL] [Abstract][Full Text] [Related]
50. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058 [TBL] [Abstract][Full Text] [Related]
51. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Ellis KL; Cameron VA; Troughton RW; Frampton CM; Ellmers LJ; Richards AM Eur J Heart Fail; 2013 Oct; 15(10):1138-47. PubMed ID: 23696613 [TBL] [Abstract][Full Text] [Related]
52. Diabetes Mellitus and Outcomes of Cardiac Resynchronization With Implantable Cardioverter-Defibrillator Therapy in Older Patients With Heart Failure. Echouffo-Tcheugui JB; Masoudi FA; Bao H; Spatz ES; Fonarow GC Circ Arrhythm Electrophysiol; 2016 Aug; 9(8):. PubMed ID: 27489243 [TBL] [Abstract][Full Text] [Related]
53. Cardiac Resynchronization Therapy for Mild Heart Failure: Compelling Evidence of Long-Term Benefits. Estes NA JACC Heart Fail; 2015 Sep; 3(9):701-2. PubMed ID: 26277766 [No Abstract] [Full Text] [Related]
54. Reducing Readmissions With Novel Cardiac Resynchronization Therapy Programming: Is Meeting the 30-Day Metric Enough? Nohria A; Desai AS JACC Heart Fail; 2015 Jul; 3(7):573-575. PubMed ID: 26071615 [No Abstract] [Full Text] [Related]
55. Female gender, myocardial remodeling and cardiac failure: are women protected from increased myocardiocyte apoptosis? Biondi-Zoccai GG; Baldi A; Biasucci LM; Abbate A Ital Heart J; 2004 Jul; 5(7):498-504. PubMed ID: 15487266 [TBL] [Abstract][Full Text] [Related]
56. The clinical and hemodynamic factors that influence the concentrations of biomarkers of myocyte injury measured by high sensitive assay PATHFAST. Sato Y; Miyamoto T; Taniguchi R; Nagao K; Matsuoka T; Fukuhara R; Kuwabara Y; Isoda K; Yamane K; Nishi K; Saijyo S; Fujiwara H; Takatsu Y J Cardiol; 2009 Feb; 53(1):20-7. PubMed ID: 19167634 [TBL] [Abstract][Full Text] [Related]
57. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005 [TBL] [Abstract][Full Text] [Related]